Purchase this article with an account.
masakazu morioka, Yoshihiro Takamura, Yutaka Yamada, makoto gozawa, takehiro matsumura, Masaru Inatani; Anterior flare intensity after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4851.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate anterior flare intensity (AFI) after intravitreal injection of aflibercept (IVA), ranibizumab (IVR) or triamcinolone acetonide (IVTA) in patients with diabetic macular edema (DME).
This study was conducted as a prospective study for the patients with DME. The patients with phakic eyes were received either IVA or IVR, and the patients with pseudophakic eyes were received 1:1:1 either IVA, IVR or IVTA. AFI and central retinal thickness (CRT) were measured with the laser flare meter and spectral domain optical coherence tomography, respectively, at days 0, 1, 7, 30 and 90.
Forty patients with phakic eyes and 60 patients with pseudophakic eyes were enrolled. In the IVTA group, AFI of pseudophakic eyes was decreased significantly at days 1 (p = 0.0487), 7 (p = 0.0201), and 30 (p = 0.0211). In the IVA groups, AFI of phakic eyes was transiently increased at day 1 (p = 0.0078) and then returned to baseline level at day 7, while no significant change was found in AFI of pseudophakic eyes. In the IVR group, there was no significant change in AFI regardless of phakic condition. All groups showed the significant reduction of CRT at days 7 and thereafter.
DME was successfully improved after the treatment of IVTA, IVR or IVA, while the reduction of AFI was noticed in the eyes treated with IVTA only. The temporal profiles of AFI is probably reflected by the difference of the pharmacological property among the drugs.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only